Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504458 | 0.91 | SIGMAR1 (0.45) | SIGMAR1OPRM1KCNH2FASN | |
| SCHEMBL20504273 | 0.82 | SIGMAR1 (0.44) | SIGMAR1OPRM1KCNH2FASN | |
| SCHEMBL20504400 | 0.80 | SIGMAR1 (0.44) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL23015985 | 0.79 | SIGMAR1 (0.42) | SIGMAR1OPRM1KCNH2FASN | |
| SCHEMBL11288204 | 0.78 | SIGMAR1 (0.74) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL738200 | 0.78 | SIGMAR1 (0.36) | SIGMAR1OPRM1FASN | |
| SCHEMBL23015945 | 0.77 | FASN (0.42) | SIGMAR1OPRM1KCNH2FASN | |
| SCHEMBL20555552 | 0.76 | USP2 (0.39) | SIGMAR1 | |
| SCHEMBL20504302 | 0.74 | SIGMAR1 (0.44) | SIGMAR1OPRM1KCNH2FASN | |
| SCHEMBL20504293 | 0.73 | SIGMAR1 (0.45) | SIGMAR1OPRM1KCNH2FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002503-A1 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2025-01-02 | — | — | US | claimed |
| EP-3377500-B1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2022-10-19 | — | — | EP | claimed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | claimed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | claimed |
| EP-3377500-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-09-26 | — | — | EP | claimed |
| US-20250002503-A1 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2025-01-02 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| EP-3377500-B1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 2970/4885 |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 2970/4885 |
| US-20250002503-A1 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | SIGMAR1, OPRD1, OPRK1 | SIGMAR1 1/4885OPRM1 4/4885KCNH2 2271/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 2970/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.